Machtinger Ronit, Tuval Atalia, Hammerman Ariel, Maman Ettie, Nahum Ravit, Orvieto Raoul, Noah Hirsh Meirav, Aizer Adva, Ziv Baran Tomer
Department of Obstetrics and Gynecology, Sheba Medical Center, Ramat Gan 52621, Israel.
School of Medicine, Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv 69978, Israel.
Diagnostics (Basel). 2025 Sep 8;15(17):2278. doi: 10.3390/diagnostics15172278.
Demand for elective oocyte cryopreservation (OC) among healthy women delaying childbearing is rising worldwide. Yet, clinicians and patients often rely on limited or indirect evidence to predict age-specific mature oocyte yield. Robust, real-world benchmarks are needed to guide expectations, estimate live birth potential, and optimize treatment planning. We retrospectively analyzed 400 healthy women aged 30-41 undergoing their first elective OC cycle between 2019 and 2023 at a large, university-affiliated fertility center. Exclusion criteria included infertility, polycystic ovary syndrome, prior ovarian surgery, and other medical indications for OC. All cycles used a standardized GnRH antagonist protocol with an initial gonadotropin dose of 300 IU/day. Only mature (metaphase II) oocytes were cryopreserved. Age-specific percentiles for total and mature oocyte yield were modeled using the General Additive Model for Location, Scale, and Shape (GAMLSS), and nomograms were developed. Mean age was 35.7 years (SD 2.3). Median total and mature oocytes retrieved were 13 (IQR 9-19) and 10 (IQR 7-15), respectively. At the 50th percentile, women aged 30, 35, and 40 yielded 20, 14, and 9 total oocytes, with 15, 11, and 6 mature oocytes cryopreserved. Nomograms across percentiles illustrated a consistent, progressive decline in yield with advancing age. Age-based nomograms derived from real-world data can offer a clinically relevant tool to estimate the likely oocyte yield per cycle. They can help set realistic expectations, guide the number of cycles needed to meet fertility goals, and support evidence-based, shared decision-making in elective OC.
在全球范围内,健康的育龄推迟女性对选择性卵母细胞冷冻保存(OC)的需求正在上升。然而,临床医生和患者常常依靠有限或间接的证据来预测特定年龄的成熟卵母细胞产量。需要可靠的真实世界基准来指导预期、估计活产潜力并优化治疗方案。我们回顾性分析了2019年至2023年间在一家大型大学附属医院生殖中心进行首次选择性OC周期的400名30至41岁的健康女性。排除标准包括不孕、多囊卵巢综合征、既往卵巢手术以及其他OC的医学指征。所有周期均采用标准化的促性腺激素释放激素拮抗剂方案,初始促性腺激素剂量为300 IU/天。仅冷冻保存成熟(中期II)卵母细胞。使用位置、尺度和形状通用加性模型(GAMLSS)对总卵母细胞产量和成熟卵母细胞产量的年龄特异性百分位数进行建模,并绘制了列线图。平均年龄为35.7岁(标准差2.3)。回收的总卵母细胞和成熟卵母细胞的中位数分别为13个(四分位间距9 - 19)和10个(四分位间距7 - 15)。在第50百分位数时,30岁、35岁和40岁的女性分别产生20个、14个和9个总卵母细胞,冷冻保存15个、11个和6个成熟卵母细胞。各百分位数的列线图显示,随着年龄增长,产量持续、逐渐下降。基于真实世界数据得出的年龄列线图可为估计每个周期可能的卵母细胞产量提供一个临床相关工具。它们有助于设定现实的预期,指导实现生育目标所需的周期数,并支持选择性OC中基于证据的共同决策。